RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function.

Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function.

Add to Collection
2023 Jun 15 Others D Dasari, SG Goyal, A Penmetsa, D Sriram… - European Journal of …, 2023 - Elsevier

Full Author : ['Dasari, Deepika', 'Goyal, Srashti Gopal', 'Penmetsa, Anuhya', 'Sriram, Dharmarajan', 'Dhar, Arti']
Journal Title : European journal of pharmacology
Chapter : Section3
Journal Year : 2023

Sodium-glucose transport protein 2 (SGLT-2) inhibitors are approved antidiabetic drugs with a beneficial effect on reducing major adverse cardiac events and heart failure hospitalization. Among them, canagliflozin has the least selectivity toward SGLT-2 o..... Read More

Keywords : ["canagliflozin protect diabetic cardiomyopathy", "improved mitochondrial function", "myocardial integrity", "mitigate fibrosis", "preserve"]
PubMed Link : https://www.sciencedirect.com/science/article/pii/S0014299923002315